SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-21-000084
Filing Date
2021-10-19
Accepted
2021-10-19 17:19:50
Documents
13
Period of Report
2021-10-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20211019.htm   iXBRL 8-K 38651
2 EX-10.1 exhibit101-oysterpointxwai.htm EX-10.1 55748
  Complete submission text file 0001720725-21-000084.txt   245927

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20211019.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20211019_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20211019_pre.xml EX-101.PRE 13053
6 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20211019_htm.xml XML 11265
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 211331957
SIC: 2836 Biological Products, (No Diagnostic Substances)